Skip to main content
. 2018 Nov 12;8(11):110. doi: 10.1038/s41408-018-0138-8

Fig. 2. Correlation of pSTAT3 expression label at diagnosis to overall survival in PTCL patients treated with standard chemotherapy.

Fig. 2

(A) Hazard ratio with 10%, 30%, and 80% cut-off pSTAT3 positivity in PTCL-NOS, AITL, ALK-neg ALCL, and ALK-pos ALCL. (B, C) Kaplan–Meier plots of the OS of AITL (B) and PTCL-NOS (C) patients with differential pSTAT3 positivity